Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade

Clinical Rheumatology

Volumn 34, Issue 3, 2015, Pages 419-427

  Makrilakis, Konstantinos ^a   Fragiadaki, Kalliopi ^a   Smith, Jacqueline ^b   Sfikakis, Petros P ^a   Kitas, George D ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Apelin; Chemerin; PAI 1; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ADIPOCYTOKINE; CHEMERIN PROTEIN, HUMAN; CHEMOKINE; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TOCILIZUMAB;

ADULT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ADIPOKINES; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CHEMOKINES; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84924704948     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2704-1     Document Type: Article

References (48)

1. John H, Toms TE, Kitas GD (2011) Rheumatoid arthritis: is it a coronary heart disease equivalent? Curr Opin Cardiol 26:327–333
2. Protogerou A, Zampeli E, Tentolouris N, Makrilakis K, Kitas G, Sfikakis PP (2012) Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-control study. Ann Rheum Dis 71:1534–1536
3. Khan F, Galarraga B, Belch JJ (2010) The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol 6:253–261
4. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW (2004) Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 50:3444–3449
5. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695
6. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963
7. Bamias G, Stamatelopoulos K, Zampeli E, Protogerou A, Sigala F, Papamichael C, Christopoulos P, Kitas GD, Sfikakis PP (2013) Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis. Clin Immunol 147:144–150
8. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentlier M, Sasaki S (2007) Chemerin—a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 362:1013–1018
9. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpene C, Audigier Y, Saulnier-Blache JS, Valet P (2005) Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146:1764–1771
10. Ernst MC, Sinal CJ (2010) Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 21:660–667
11. Kopeikina LT, Kamper EF, Coutsoukos V, Bassiakos Y, Stavridis I (1997) Imbalance of tissue-type plasminogen activator (tPA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol 16:254–260
12. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 40:640–644
13. Dimitroulas T, Douglas KM, Panoulas VF, Toms T, Smith JP, Treharne GJ, Nightingale P, Hidson J, Kitas GD (2013) Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors. Clin Rheumatol 32:1357–1364
14. Gray RP, Patterson DL, Yudkin JS (1993) Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb 13:415–420
15. Zampeli E, Protogerou A, Stamatelopoulos K, Fragiadaki K, Katsiari CG, Kyrkou K, Papamichael CM, Mavrikakis M, Nightingale P, Kitas GD, Sfikakis PP (2012) Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. Arthritis Res Ther 14:R44. doi:10.1186/ar3757
16. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331
17. Cronstein BN (2007) Interleukin-6—a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 65(Suppl 1):S11–S15
18. Ohsugi Y, Kishimoto T (2008) The recombinant humanized antin-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 8:669–681
19. Herenius MM, Oliveira AS, Wijbrandts CA, Gerlag DM, Tak PP, Lebre MC (2013) Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation. PLoS One 8:e57802. doi:10.1371/journal.pone.0057802
20. Genre F, Miranda-Filloy JA, Lopez-Mejias R, Carnero-Lopez B, Ochoa R, Rueda J, Gonzalez-Juanatey C, Blanco R, Llorca C, Gonzalez-Gay MA (2013) Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 31:532–537
21. Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N (2007) Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17:385–390
22. Miranda-Filloy JA, López-Mejias R, Genre F, Carnero-Lopez B, Ochoa R, Diaz de Teran T, Gonzalez-Juanatey C, Blanco R, Llorca C, Gonzalez-Gay MA (2013) Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 31:365–371
23. Miranda-Filloy JA, López-Mejias R, Genre F, Carnero-Lopez B, Ochoa R, Diaz de Teran T, Gonzalez-Juanatey C, Blanco R, Llorca C, Gonzalez-Gay MA (2013) Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 31:538–545
24. Jin T, Bokarewa M, Amu S, Tarkowski A (2009) Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol 27:491–494
25. Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M (2010) Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumotol 28:254–257
26. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N (2013) Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204345
27. van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, Pedersen R, Fatenejad S (2005) Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64:1582–1587
28. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, Wells G, Lange ML, Felson DT (1999) ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 26:705–711
29. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850
30. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentifuge. Clin Chem 18:499–502
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
32. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–2410
33. Fonseca JE, Santos MJ, Canhao H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538–542
34. Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP (2011) A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 219:734–746
35. Sarecka B, Zak I, Krause J (2008) Synergistic effects of the polymorphisms in the PAI-1 and the IL-6 genes with smoking in determining their associated risk with coronary artery disease. Clin Biochem 41:467–473
36. Rega G, Kaun C, Weiss TW, Demyanets S, Zorn G, Kastl SP, Steiner SP, Seidinger D, Kopp CW, Frey M, Roehle R, Maurer G, Huber K, Wojta J (2005) Inflammatory cytokines interleukin-6 and oncostatin M induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 111:1938–1945
37. Lipsky P (2006) Interleukin-6 and rheumatic diseases. Arthritis Res Ther 8(Suppl 2):S4
38. Hart R, Greaves DR (2010) Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol 185:3728–3739
39. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichorn J, Mahajan R, Agrawal R, Greve J, Robbins R, Patterson AJ, Bernstein D, Quertermous T (2005) The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 65:73–82
40. Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, Ayav A, Ziegler O, Carpene C, Saulnier-Blache JS, Valet P, Castan-Laurell I (2006) TNF alpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 20:1528–1530
41. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148:4687–4694
42. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Goke B, Leber AW, Parhofer KG, Broedl UC (2009) Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 161:339–344
43. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, Mahaney MC, Rainwater DL, VandeBerg JL, MacCluer JW, Collier G, Blangero J, Walder K, Jowett JB (2009) Chemerin is associated with metabolic syndrome phenotypes in a Mexican American population. J Clin Endocrinol Metab 94:3085–3088
44. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R, Iida K, Okimura Y, Kaji H, Kasuga M, Chihara K (2008) Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 582:573–578
45. Schultz O, Oberhauser O, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M (2010) Effects of inhibition of interleukin-6 signaling on insulin sensitivity and lipoprotein(a) levels in human subjects with rheumatoid arthritis. PLoS One 5:e14328
46. Reaven GM (2013) What do we learn from measurements of HOMA-IR? Diabetiologia 56:1867–1868
47. Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y (1992) Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 35:1197–1212
48. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2632